Geode Capital Management LLC Acquires 19,095 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Geode Capital Management LLC lifted its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 0.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,309,778 shares of the company’s stock after buying an additional 19,095 shares during the quarter. Geode Capital Management LLC owned about 1.68% of Compass Therapeutics worth $4,251,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics during the 3rd quarter worth $25,000. Intech Investment Management LLC bought a new position in shares of Compass Therapeutics during the third quarter worth $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the third quarter worth about $37,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics during the second quarter worth about $41,000. Finally, SG Americas Securities LLC boosted its stake in Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares during the period. 68.43% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CMPX has been the topic of several recent research reports. D. Boral Capital initiated coverage on Compass Therapeutics in a research note on Monday, December 23rd. They issued a “buy” rating and a $32.00 price target on the stock. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. Finally, Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $5.00 to $4.00 in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Trading Up 11.4 %

Shares of NASDAQ CMPX opened at $1.56 on Monday. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $2.34. The firm has a market cap of $214.64 million, a P/E ratio of -4.22 and a beta of 0.89. The business’s 50 day moving average is $1.57 and its 200-day moving average is $1.43.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Analysts forecast that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.